Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: Results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study

BACKGROUND: B cells may be involved in the pathophysiology of multiple sclerosis (MS). Inebilizumab (formerly MEDI-551) binds to and depletes CD19(+) B cells. OBJECTIVES: To assess safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of inebilizumab in adults with relapsing MS...

Descripción completa

Detalles Bibliográficos
Autores principales: Agius, Mark A, Klodowska-Duda, Gabriela, Maciejowski, Maciej, Potemkowski, Andrzej, Li, Jing, Patra, Kaushik, Wesley, Jacob, Madani, Soraya, Barron, Gerard, Katz, Eliezer, Flor, Armando
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2017
Materias:
Original Research Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6360486/
https://www.ncbi.nlm.nih.gov/pubmed/29143550
http://dx.doi.org/10.1177/1352458517740641

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6360486/
https://www.ncbi.nlm.nih.gov/pubmed/29143550
http://dx.doi.org/10.1177/1352458517740641

Ejemplares similares